Association of PD-1 Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma
Share The Content :
(Refresh the page or download this document incase the PDF doesn’t load properly)
